Reference number : 236-2014-2015-Q3-00070, amendment number : , agreement type : G, recipient legal name : HALPERIN, Scott A, recipient country : CA, recipient province : NS, recipient city : Halifax, recipient postal code : B3H 3J5, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 305910.0, agreement start date : 2014-10-01, agreement end date : 2015-06-30, description english : A phase 1 Randomized, Single-Centre, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects, description french : A phase 1 Randomized, Single-Centre, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2014-15 to 2015-16), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2014-15 à 2015-16), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada